AI-Designed Drug Shows Early Signs of Reversing Biological Aging Markers

Insilico Medicine’s rentosertib, an AI-designed drug candidate originally developed for idiopathic pulmonary fibrosis, showed signs of reversing markers of biological aging in a new analysis published in Nature Biotechnology. The trial involved 42 patients, and blood samples were analyzed for protein patterns associated with biological age. According to the report, treated patients were read as biologically younger than the placebo group by six independent aging clocks.

The researchers ran six independent AI aging clocks on patient blood data. All six pointed in the same direction: lower predicted biological age among patients treated with rentosertib compared with placebo. The strongest reported signal was a three- to four-year drop by week 4, with one clock showing as much as six years, though this means the blood-protein patterns looked younger to the models rather than proving patients became measurably younger.

The findings are encouraging but far from definitive. The analysis is based on a small 42-patient trial and rentosertib has not been tested in healthy people for this purpose. Experts cited in the report cautioned that biological clocks are not always reliable and that the effect may be tied to improved lung function or reduced disease-related strain rather than a broader anti-aging effect.

Insilico used two AI systems to identify disease-relevant proteins and generate matching molecules. The company targeted TNIK, a protein linked in the article to aging and pulmonary fibrosis, and moved from target protein to drug candidate in about 18 months. Rentosertib is now in a Phase III trial for IPF, the final clinical stage before potential approval.